New multiple therapy of resistant and relapsing dermatophyte infections during epidemic status
DOI:
https://doi.org/10.66344/jpad.v32i3.1994Abstract
Background Resistant dermatophytosis is now present in many countries where fungal skin infection is a major health problem like Iraq and neighboring countries.
Objective To evaluate the efficacy of a novel therapeutic regimen in the management of resistant dermatophytosis using multiple drug therapies.
Methods This is a prospective therapeutic research where 400 cases with varying kinds of dermatophytosis were included and managed by new 2 phases of therapy, each four weeks period and as follow: Phase one using combination of oral terbinafine and oral ketoconazole and topical terbinafine cream plus selenium sulfide shampoo. While phase two including combination of oral terbinafine and oral itraconazole and topical terbinafine cream plus ketoconazole shampoo to achieve complete cure rate. Follow-up was done for eight weeks to record relapse of fungal infection.
Results This study included 400 patients with chronic relapsing dermatophytosis, 250 (62.5%) males and 150 (37.5%) females, their ages ranged from 6-70 years. The duration of the disease ranged from 6-32 months with a mean of 11 months. The response to the phase one therapeutic regimen started after 5-7 days by decreasing in the redness, itching, inflammation, and scales. An obvious response was seen at the end of the first two weeks while complete recovery response was achieved after four weeks. Phase two also showed 100% cure rate. Follow up for eight weeks showed 2% relapse rate. This combination was well tolerated with no serious systemic or topical adverse effects recorded in most of the patients.
Conclusion This new therapeutic multiple drug therapy is effective in all types of dermatophytosis especially with chronic resistant course of the disease with very low relapse rate.
References
1. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51:2–15.
2. Ajello L. Geographic distribution and prevalence of the dermatophytes. Ann N Y Acad Sci. 2006;89:30-8.
3. Sharquie K E, Jabbar R I. Major outbreak of dermatophyte infections leading into imitation of different skin diseases: trichophyton mentagrophytes is the main criminal fungus. J Turk Acad Dermatol. 2021;15(4):91-100.
4. Taghipour S, Shamsizadeh F, Pchelin IM, Rezaei-Matehhkolaei A, Zarei Mahmoudabadi A, Valadan R, et al. Emergence of terbinafine resistant trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene. Infect Drug Resist. 2020;13:845-50.
5. Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62:227-36.
6. Uhrlass S, Alhilaifawi AFH, Sharquie KE, Alhamami HR, Al-Qahar GHA, Tabra MKH, et al. Dermatophyte survey from Baghdad, Iraq – emergence of terbinafine resistant Trichophyton mentagrophytes Type VIII India. Submitted (MAY- 2020) to the EMBL/GenBank/DDBJ databases.
7. Nenoff P, Verma SB, Ebert A, Süß A, Fischer E, Auerswald E, et al. Spread of terbinafine-resistant Trichophyton mentagrophytes Type VIII (India) in Germany-”The Tip of the Iceberg?”. J Fungi (Basel). 2020;6:207.
8. Verma, S.B. Comment on: Emergence of recalcitrant dermatophytosis in India. Lancet Infect Dis. 2018;18:718–9.
9. Bishnoi A, Vinay K, Dogra S. Emergence of recalcitrant dermatophytosis in India. Lancet Infect Dis. 2018;18:250–1.
10. De Doncker P, Pande S, Richarz U, Garodia N. Itraconazole: What clinicians should know? Indian J Drugs Dermatol. 2017;3:4-10.
11. Panda S, Verma S. The menace of dermatophytosis in India: The evidence that we need. Indian J Dermatol Venereol Leprol. 2017;83:281-4.
12. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693-715.
13. Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529-34.
14. Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis. J Dermatolog Treat. 2020;31(7):749-53.
15. Sharquie K E, Noaimi A A, and Al-Salam W S. The safety of oral ketoconazole in the treatment of skin diseases (Single blinded, therapeutic, comparative study). J Cosmet Dermatol Sci Appl.2018;8:264-71.
16. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005;19:21-9.
17. Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol. 2003;149(65):15–8.
18. Evans EGV. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol. 2003;149(65):11–3.
19. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17.
20. Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res. 1992; 24:367-70.
21. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/ corporis. Br J Dermatol. 1994;131:684-6.
22. Noppakun N, Phuphaibool K. Treatment of dermatophytosis with new systemic antifungal agent, itraconazole. J Med Assoc Thai. 1992;75:99-103.
23. Acharya KM, Mukhopadhyay A, Thakur RK, Mehta T, Bhuptani N, Patel R. Itraconazole versus griseofulvinin the treatment of tinea corporis and tinea cruris. Indian J Dermatol Venereol Leprol. 1995;61:209-11.
24. De Keyser P, De Backer M, Massart DL, Westelinck KJ. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol. 1994;130:22-5.
25. Bourlond A, Lachapelle JM, Aussems J, Boyden B, Campaert H, Conincx S, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol. 1989;28:410-2.
26. Majid I, Sheikh G, Kanth F, Hakak R. Relapse after oral terbinafine therapy in dermatophytosis: A clinical and mycological study. Indian J Dermatol. 2016;61:529-33.
27. Ellabib MS,Khalifa Z,Kavanagh K.Dermatophytes and other fungi associated with skin mycoses in Tripoli, Libya. Mycoses. 2002;45:101-4.
28. Mahmoud AL. A study of dermatophytoses in Sana’a, Yemen Republic. Mycoses. 2002;45:105-8.
29. Lange M, Nowicki R, Barańska-Rybak W, Bykowska B. Dermatophytosis in children and adolescents in Gdansk, Poland. Mycoses. 2004;47:326-9.
30. Sowmya N, Appalaraju B, Surendran P, Srinivas CR. Isolation, identification and comparatative analysis of SDA and DTM for dermatophytes from clinical samples in a tertiary care hospital. IOSR J Dent Med Sci. 2014;13:68-73.
31. Rashidian S, Falahati M, Kordbacheh P, Mahmoudi M, Safara M, Sadeghi Tafti H, et al. A study on etiologic agents and clinical manifestations of dermatophytosis in Yazd, Iran. Curr Med Mycol. 2015;1:20-5.
32. Atzori L, Pau M, Aste N, Aste N. Dermatophyte infections mimicking other skin diseases: a 154-person case survey of tinea atypica in the district of Cagliari (Italy). Int J Dermatol. 2012;51:410-5.
33. Sharquie KE, Al Ani SM, Ali TM. Microsporum canis epidemic in Iraq children. Journal of the Faculty of Medicine-Baghdad. 1992;34:95-99.
34. Mohammed SJ, Noaimi AA, Sharquie KE. A survey of dermatophytes isolated from Iraqi patients in Baghdad city. AL-Qadisiya Medical Journal. 2015;11:10-15.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Khalifa E. Sharquie, Raed I. Jabbar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
